Publication for CYP4F2 and CYP4F11

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	CYP4F2	cytochrome P450 family 4 subfamily F member 2	8529			[link]
hsa	CYP4F11	cytochrome P450 family 4 subfamily F member 11	57834

Pubmed ID	Priority	Text
18662666	0.98	CYP4F2 carboxyl terminal hexapeptide recognized neither CYP4F11 nor CYP4F12 but cross-reacted strongly with CYP4F3b6.
	0.97	CYP4F2, such as CYP4F3b, CYP4F11 or CYP4F12, also function as catalysts of fatty acid and LTB4 omega-hydroxylation.
	0.96	CYP4F2 and total immunoreactive CYP4F (quantitated using anti- CYP4F+ IgG), suggesting that hepatic CYP4F2 expression is regulated in a manner different than that of CYP4F3b, CYP4F11, and/or CYP4F12.
	0.96	CYP4F2 levels and total immunoreactive CYP4F content among the 29 subjects, suggesting that the regulation of CYP4F2 protein expression in liver is not coordinate with that of CYP4F3b, CYP4F11, and/or CYP4F12.
	0.96	CYP4F2 and CYP4F2-containing supersomes (Table 1) no correlation was found between CYP4F2 protein expression and oleate 18-hydroxylation (Fig. 5C), an observation which suggests that CYP4F3b and, perhaps, CYP4F11 function as more efficient cataysts of this reaction in intact liver microsomes.
	0.96	CYP4F2, CYP4F3b, CYP4F11, and CYP4F12 cDNA-deduced amino acid sequences is shown from residues 1 through 520-524.
	0.95	CYP4F2, CYP4F3b, CYP4F11, and CYP4F12 cDNA-deduced amino acid sequences, which range in length from 520-524 residues, gave 74.8% overall sequence homology (Fig. 1B) whereas the alignment of any two of these CYP4F P450 protein sequences gave 81-93% similarity.
	0.94	CYP4F2, CYP4F3b, CYP4F11 and CYP4F12.
	0.94	CYP4F2 IgG2 was employed in our prior studies on CYP4F2 involvement in hepatic and renal 20- HETE formation and LTB4 catabolism, although it is now known that this antibody reacts not only with CYP4F2 but also with CYP4F3b, CYP4F11, CYP4F12 and CYP4F3a.
	0.91	CYP4F2, CYP4F3b, CYP4F11 and CYP4F12 are found in liver and kidney whereas CYP4F3a is found only in myeloid tissue and CYP4F8 is expressed exclusively in seminal vesicles.
	0.87	CYP4F2 peptide antibodies recognized only CYP4F2 and not CYP4F3b, CYP4F11 or CYP4F12.
	0.77	CYP4F2 (0.1 microg); lane 2 and 7, purified CYP4F3b (0.1 microg); lanes 3 and 8, CYP4F11-containing Sf9 insect cell lysates (5 microg); lanes 4 and 9, CYP4F12-containing Sf9 insect cell lysates (1 microg); lanes 5 and 10, liver microsomes from subject G (15 microg).
	0.74	CYP4F2 amino acid residues 61-74 (WGHQGMVNPTEEG) and 65-77 (GMVNPTEEGMRVL) recognized on immunoblots only CYP4F2 and not CYP4F3b, CYP4F11 or CYP4F12.
	0.52	CYP4F2, CYP4F3a, CYP4F3b, CYP4F8, CYP4F11 and CYP4F12, which possess 74% overall amino acid sequence homology.
28620303	0.97	CYP4F11 and CYP4F12 mRNA showed significant albeit not very strong correlations with CYP4F2 mRNA (rs = 0.25 and 0.384, respectively, P < 0.01; Figures 1A,B) and with each other (rs = 0.3, P < 0.001; Figure 1D).
	0.97	CYP4F2 mRNA expression, rs2108622 demonstrated a significant association with decreased CYP4F11 mRNA levels (Pc = 6.06 x 10-4, R2 = 13.7%, Figure 2D) while rs2189784 was significantly associated with lower levels of CYP4F12 mRNA expression (Pc = 0.031, R2 = 8.3%, Figure 2B).
	0.97	CYP4F2 rs2108622 and CYP4F11 rs1060467 as illustrated in Table 5, it can be seen that there were small dose changes in patients carrying haplotypes consisting of CYP4F2 rs2108622 wild-type genotype and CYP4F11 rs1060467 variant genotype and vice versa.
	0.97	CYP4F2 rs2108622, the association of warfarin stable dose with CYP4F11 rs1060467 disappeared (Pcinitial = 0.017, Pcconditional = 0.418).
	0.97	CYP4F2 rs2108622 and/or CYP4F11 rs1060467 improves warfarin dose predictive accuracy, we developed a clinical algorithm and several pharmacogenetic algorithms as shown in Table 6.
	0.97	CYP4F2 rs2108622 or CYP4F11 rs1060467 to the pharmacogenetic algorithm explained a further 0.5-0.7% in warfarin dose variability with a modest increase in prediction accuracy (~1% decrease in MAE and 1.2% increase in the number of predicted dose which fell within +-20% of the observed warfarin dose).
	0.96	CYP4F2-CYP4F11 region.
	0.96	CYP4F2 rs2108622 and CYP4F11 rs1060467 remained the most significant among all the CYP4F2 and CYP4F11 SNPs, respectively.
	0.96	CYP4F2 rs2108622 can explain the association signal for CYP4F11 rs1060467 or vice versa.
	0.96	CYP4F2, CYP4F11, and CYP4F12 genes using the publicly available eQTL database hosted by the Pritchard laboratories at the University of Chicago.
	0.96	CYP4F2, CYP4F11, and CYP4F12 polymorphisms on the hepatic expression levels of CYP4F2, CYP4F8, CYP4F11, and CYP4F12 mRNA in a Caucasian population.
	0.96	CYP4F2 was associated with decreased CYP4F11 mRNA expression accounting for nearly 14% of CYP4F11 hepatic mRNA expression.
	0.96	CYP4F11 rs1060467 or CYP4F2 rs2108622 or both CYP4F11 rs1060467 and CYP4F2 rs2108622, explained a similar increase in warfarin dose variability with modest improvement in prediction accuracy (1-2%), indicating that just one of these SNPs can explain the effect on warfarin dose variability.
	0.95	CYP4F11 demonstrated a significant association with decreased CYP4F2 mRNA expression (Pc = 0.031, R2 = 7.2%, Figure 2E); whilst an opposite trend for increasing CYP4F11 mRNA expression was observed which was not statistically significant after FDR (Pc = 0.310, Figure 2F).
	0.95	CYP4F11 rs1060467; (B) CYP4F2 rs2108622; (C) intergenic rs7248867; (D) CYP4F12 rs2074568.
	0.95	CYP4F2, CYP4F11, and CYP4F12 affect the mRNA expression levels of CYP4F2, CYP4F11, and CYP4F12 in human liver tissues and that CYP4F11 plays a role in warfarin response.
	0.95	CYP4F11 region, rs1060467, was associated with decreased CYP4F2 mRNA expression, accounting for 7% of the variability in CYP4F2 mRNA expression.
	0.94	CYP4F11 (P = 0.25) and CYP4F2 (P = 0.537).
	0.93	CYP4F2, CYP4F11, and CYP4F12 haplotypes on hepatic mRNA expression of the CYP4F gene cluster were evaluated and significant associations are reported in Table 3.
	0.92	CYP4F2, CYP4F3, CYP4F8, CYP4F11, and CYP4F12 reside together on chromosome 19p13.1-2, spanning over 320 kb (Supplementary Figure 1).
	0.92	CYP4F2 rs2108622 and CYP4F11 rs1060467.
	0.92	CYP4F11 rs1060467, a reduction in both magnitude and significance was seen with the association of warfarin stable dose with CYP4F2 rs2108622 (betainitial = 0.078, betaconditional = 0.063, Pcinitial = 0.003, Pcconditional = 0.05).
	0.88	CYP4F2, CYP4F11, and CYP4F12 and their effect on mRNA expression.
	0.86	CYP4F11 rs1060467 and CYP4F2 rs2108622 in the CYP4F gene cluster do not appear to affect warfarin dose requirement.
	0.83	CYP4F2, CYP4F11, and CYP4F12 were associated with mRNA expression in the CYP4F gene cluster.
	0.83	CYP4F2, CYP4F3, CYP4F8, CYP4F11, and CYP4F12 are almost identical, suggesting that this cluster of five genes may have evolved by gene duplication.
	0.79	CYP4F2, with CYP4F11 transcript levels in livers from individuals of European descent.
	0.78	CYP4F2, CYP4F11, CYP4F12 mRNA in normal liver tissue donated from 149 patients in relation to corresponding SNPs across the CYP4F2-CYP4F11 locus.
	0.77	CYP4F2-CYP4F11 Region on Hepatic mRNA Expression of the CYP4F Gene Cluster
	0.75	CYP4F2 rs2108622 was associated with increased CYP4F2 expression while CYP4F11 rs1060467 was associated with decreased CYP4F2 expression.
	0.74	CYP4F2 and CYP4F11 on warfarin dose variability is very small in our population.
	0.73	CYP4F2-CYP4F11 locus, suggesting that SNPs across the CYP4F11 and CYP4F12 regions could be associated with mRNA expression of CYP4F2 and possibly other CYP4F gene cluster members.
	0.67	CYP4F2, CYP4F11 and CYP4F12 genes in appropriately phenotyped patients on warfarin may help identify these.
27612091	0.97	CYP4F2 and CYP4F11) in humans (Edson et al., 2013).
24138531	0.96	CYP4F2 and CYP4F11 were expressed and purified and found to be equally efficient as in vitro catalysts of MK4 omega-hydroxylation.
	0.96	CYP4F11, expressed in E. coli and purified as previously described, was reconstituted with DLPC, cytochrome b5, and P450 oxidoreductase, and its ability to oxidize MK4 and phylloquinone was compared with that of purified, reconstituted CYP4F2.
	0.96	CYP4F2 and CYP4F11 were 14.3 +- 6.3 pmol/mg protein and 8.4 +- 1.5 pmol/mg protein, respectively (Fig. 9).
	0.96	CYP4F2 and CYP4F11 substrate.
	0.96	CYP4F2 and CYP4F11 are vitamin K1 and K2 omega-hydroxylases and that CYP4F2, at least to some extent, sequentially metabolizes vitamin K to the omega-carboxy metabolite.
	0.96	CYP4F2 (left) and CYP4F11 (right) with PK (top) and MK4 (bottom) substrates.
	0.96	CYP4F2 and CYP4F11 protein levels in human liver microsomes measured by peptide LC-MS/MS.
	0.96	CYP4F2 protein content (R2 = 0.13, P = 0.05) and did not correlate with CYP4F11 protein content (R2= 0.05; P = 0.36).
	0.93	CYP4F2, but not CYP4F11, catalyzed sequential metabolism of MK4 to the omega-acid without apparent release of the intermediate aldehyde.
	0.92	CYP4F2*3 (V433M) and CYP4F11 (D446N) alleles.
	0.88	CYP4F2*3 homozygotes (5-10% of Caucasian populations), we predict that CYP4F11 enzyme activity would be a more important contributor to MK4 omega-hydroxylation, irrespective of CYP4F11 genotype.
	0.87	CYP4F2 would, in general, be a more dominant contributor to the initiation of MK4 catabolism than CYP4F11.
	0.87	CYP4F2 genotype, either CYP4F2 or CYP4F11 is the more dominant contributor to initiation of vitamin K catabolism.
	0.86	CYP4F11 and identify a common variant, CYP4F2 (rs2108622), as a major pharmacogenetic variable influencing MK4 catabolism.
	0.85	CYP4F2 and CYP4F11 in Human Liver Microsomes by Tryptic Peptide LC-MS/MS
	0.82	CYP4F11 (and CYP4F2) in human liver microsomes by tryptic peptide LC-MS/MS, using trypsin digests of purified CYP4F11 and CYP4F2 (calibration standard) and corresponding isotopically-labeled peptides (internal standards) for robust quantitation.
	0.79	CYP4F2, CYP4F3B, CYP4F11, and CYP4F12 are all readily detectable at the mRNA level.
	0.75	CYP4F2 is an omega-hydroxylase of MK4, characterize formyl and carboxylic acid metabolites that results from further oxidation of the primary metabolic product, establish an 'orphan' P450, CYP4F11, as a new vitamin K omega-hydroxylase and quantitate CYP4F2 and CYP4F11 in human liver microsomes by LC-MS/MS in order to scale the relative contributions of these two P450 enzymes to initiation of vitamin K catabolism.
	0.73	CYP4F2 Supersomes, B, reconstituted CYP4F2, C, reconstituted CYP4F11.
	0.71	CYP4F2 will be a more dominant contributor to initiation of vitamin K catabolism, except in CYP4F2*3 homozygotes, where CYP4F11 would be expected to become a more prominent contributor.
	0.64	CYP4F2 and CYP4F11 to be 14.3 and 8.4 pmol/mg protein, respectively.
	0.63	CYP4F2 content and MK4 omega-hydroxylation activity (P = 0.05, R2 = 0.13) and no correlation with CYP4F11 content (Fig. 9).
	0.60	CYP4F11 was present at approximately half the concentration of CYP4F2 in human liver microsomes.
25946405	0.96	CYP4F2, CYP4F11, and GGCX were resequenced in 94 CANHR participants and 188 SCF participants to identify any novel population-specific variation.
	0.96	CYP4F2 M519L (rs3093200) substitution, the CYP4F2 amino acid 185 change from glycine to valine (G185V rs3093153), and the CYP4F11 amino acid 276 change from arginine to cysteine (R276C rs8104361).
	0.92	CYP4F2, CYP4F11, and GGCX, each gene was resequenced in a sample of AI/AN study participants.
	0.78	CYP4F2, CYP4F11, and GGCX, which encode enzymes important for the activity of warfarin and synthesis of vitamin K dependent blood clotting factors.
	0.73	CYP4F2, CYP4F11, GGCX
29218011	0.96	CYP4F2 rs309319, and CYP4F11 rs11086013, for which we observed FST values between 0.15 and 0.33.
	0.53	CYP4F11, CYP4F2, PROS, and GGCX.
30048707	0.96	CYP4F2, but others, including CYP4F11 and CYP4F3 have some capacity to produce 20-HETE.
31244779	0.96	CYP4F2, CYP4F3, CYP4F11, CYP4F12, CYP19A1, CYP21A2, CYP24A1, and CYP3A4.
31480463	0.95	CYP4F2 and CYP4F11 are involved in the metabolism of vitamin K, facilitating vitamin K inactivation and elimination.
	0.90	CYP4F2 (rs2074900) and CYP4F11 (rs8104361) in a Western European population.
	0.90	CYP4F2, CYP4F3, CYP4F11, and CYP4F12 using common coding SNPs.
17500592	0.95	CYP4F2, CYP4F3, CYP4F8, CYP4F11, and CYP4F12.
	0.93	CYP4F2, CYP4F3, CYP4F11, and CYP4F12) or in tracheal tissue (CYP4X1), which are tissues where other xenobiotic CYP450 genes are known to function.
23688133	0.94	CYP4F2, CYP4F11, CYP4F3A and CYP4F3B.
	0.93	CYP4F2, CYP4F3B, CYP4F11, and CYP4F12 are mainly expressed in liver and kidney.
	0.86	CYP4F2, CYP4F3A, CYP4F3B, CYP4F8, CYP4F11, CYP4F12, and CYP4F22 are the seven members of the human CYP4F subfamily.
	0.71	CYP4F2 and CYP4F3B, but not CYP4F11 or CYP4F12, revealed 1.6-1.9-fold increases in protein in HepG2 cells upon treatment with the AMPK activators.
19714871	0.92	CYP4F11 and 8B1 were additionally identified, and it was also possible to differentiate CYP4F2 from 4F3 (supplemental data, Table S3).
29916051	0.86	CYP4F2, CYP4F3, CYP4F11, CYP7B1, CYP26B1 and CYP27B1.
23293373	0.82	Cyp4F11 and (B) Cyp4F2 and (C) levels of PGE2 in MSC before and after adipogenic differentiation (adipocytes).
29695969	0.82	CYP4F11; p = 0.001 and 0.013, respectively), and rs2074900 (located in CYP4F2; p = 0.001) associated with therapeutic responses to erlotinib.
26795600	0.81	CYP4F2 followed by CYP4F11 and CYP4F12 genes (Table 2).
	0.70	CYP4F2 rs3093088, CYP4F8 rs28669833 and CYP4F11 rs12610962, bearing associations of CYPF2, CYP4F8 and CYP4F11 genes, respectively, were individually associated with at least one disease severity phenotype (Table 3).
20727847	0.79	CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12 have been reasonably well characterized, whereas the properties and functions of the other five members of the family, CYP4A22, CYP4F22, CYP4V2, CYP4X1, and CYP4Z1 remain relatively obscure.
30821933	0.77	CYP4F2 g72220026G, CYP4F2*3, CYP4F2 G185V, CYP4F11 R276C, and CYP2C9*2 and *3 did not seem to be associated with warfarin dose requirement.
26233909	0.75	CYP4F2, CYP4F3B, and CYP4F11 all catalyze formation of 20-HETE and are expressed in the liver and kidney, both major sites of 20-HETE synthesis.
25370453	0.67	CYP4F11, CYP4F12) protein was present in all patients, even those without detectable CYP4F2 protein.
29023376	0.66	CYP4F2 (liver and kidney), CYP4F3A (bone marrow and neutrophiles), CYP4F3B (liver and kidney), CYP4F8 (prostate), CYP4F11 (liver, kidney, heart, and skeletal muscle), CYP4F12 (gastrointestinal tract, heart, and kidney), and CYP4F22 (skin).
30280198	0.53	CYP4F2, CYP4F3, CYP4F11 and CYP4V2 were significantly decreased in patients with higher histological and TNM stages (Figs. 2 and 3).